A study where we have employed orthogonal target validation strategies with 3 orthogonal LOF technologies (CRISPRko, CRISPRi, and siRNA) with genes involved in maintenance of the mesenchymal-to-epithelial transition (MET).
4 result(s)
The reasoning and research behind our Dharmacon™ CRISPRi platform recently published in The CRISPR Journal.
The presence of off-targets effects can greatly complicate the interpretation of experimental data. Dharmacon™ ON-TARGETplus™ siRNAs and CRISPRmod CRISPRi system are designed to knock down the target gene with minimal off-target effects and are powerful tools for orthogonal validation strategies resulting in highly specific readouts.
Gene modulation is now more flexible and accessible thanks to Horizon's new CRISPRmod CRISPRi portfolio. The system leverages an inactive Cas9 complex to block transcription resulting in precision targeted gene down regulation. Read more about our newest offering: